Capricor on April 3 said it was continuing to develop its exosome platform technology as a potential COVID-19 vaccine, even as it pursued compassionate use approval for CAP-1002 (See above). The company seeks to develop two candidates. The first is a virus-like particle (VLP) similar in structure to an exosome, and produced by the same process developed by Capricor in its studies of CAP-1002. The other is an exosome-mRNA vaccine formulation designed to elicit a protective, long-lasting immune response to SARS-CoV-2 by targeting all four structural proteins of the virus.
Candidates: Two vaccine candidates for the potential prevention of COVID-19.
Category: VAX
Types: Vaccines based on exosomes derived from the company’s proprietary cardiosphere-derived cells CDCs (CAP-2003) and engineered exosomes, both of which are in preclinical development.
Comments are closed.